OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Dr. Anderson has over 7 years of experience in cancer drug discovery and early-stage research. Prior to joining Cleave in early 2012, Dr. Anderson contributed to a number of oncology-focused small molecule drug discovery programs at Genentech. During this period he led a group responsible for developing novel cellular assays to report on drug activity and mechanism of action. His group contributed key mechanistic insights into the function of clinically approved drugs targeting the MAPK pathway and apoptosis. Dr. Anderson received a PhD in cell biology and biochemistry from the University of California, San Diego in conjunction with the Salk Institute where he was awarded the Martin D. Kamen Cell Biology Thesis Prize. He earned his BS degree in Biology from the University of Pittsburgh. Dr. Anderson has authored over 20 scientific publications including several in top-tier journals.
